An Expert Working Group has completed a review into how the potential risks associated with antidepressant medicines are communicated to patients
Similar Posts
Government cuts red tape to revolutionise public services with cutting-edge tech
The government has announced it is slashing the red tape that holds back groundbreaking innovations from coming to market.
Side effects from drug interactions to be predicted by AI before reaching patients
The MHRA leads three new government-backed projects using AI-driven approaches to make medicines safer and bring treatments to patients more quickly.
Paracetamol and pregnancy – reminder that taking paracetamol during pregnancy remains safe
Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever for pregnant women, used at the lowest dose and for the shortest duration. It also acts as an antipyretic and is therefore used to treat fever.
Apply for manufacturer or wholesaler of medicines licences
How to apply for, update and cancel licences for the manufacture, import and wholesale of human and veterinary medicines.
Sir David Spiegelhalter: Regulation in an age of personalised medicine
The internationally renowned expert in the calculation and communication of risk and statistics, Sir David Spiegelhalter, discusses the concept of a ‘preference zone’ to frame the demands of safety, efficacy and choice in the era of personalised medicine.
Clinical trials for medicines: modifying a clinical trial approval
Guidance on the various types of modifications that can be made to a clinical trial approval.